Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function

Aharon Kessel, Hana Ammuri, Regina Peri, Elsa R. Pavlotzky, Miri Blank, Yehuda Shoenfeld and Elias Toubi

*J Immunol* 2007; 179:5571-5575; doi: 10.4049/jimmunol.179.8.5571
http://www.jimmunol.org/content/179/8/5571

References This article cites 31 articles, 7 of which you can access for free at:
http://www.jimmunol.org/content/179/8/5571.full#ref-list-1

Why *The JI*? Submit online.

- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Fast Publication! 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function

Aharon Kessel,* Hana Ammuri,* Regina Peri,* Elsa R. Pavlotzky,* Miri Blank,† Yehuda Shoenfeld,‡ and Elias Toubi*‡

Intravenous Ig therapy (IVIg) is reported to be a useful regimen in treating autoimmune diseases. In this study, we asked whether IVIg (in vitro) could increase the expression of TGF-β, IL-10, and the transcription factor FoxP3 in T regulatory (Treg) cells, and the idea that IVIg could enhance suppressive properties of these cells. CD4+ T cells from 12 healthy individuals were cultured in the presence or absence of IVIg vs human control IgG during 16, 24, and 36 h. Using FACS analysis and gating on CD4+CD25high Treg cells, we assessed the expression of intracellular TGF-β, IL-10, and FoxP3. In addition, the production of TNF-α by stimulated CD4+ T cells alone or in culture with CD25+ by itself or together with IVIg was also assessed. The presence of IVIg with Treg cells in culture significantly increased the intracellular expression of TGF-β (17.7 ± 8.5% vs 29.8 ± 13%; p = 0.02), IL-10 (20.7 ± 4.7% vs 34.2 ± 5.2%; p = 0.008) and FoxP3 (20.8 ± 5.2% vs 33.7 ± 5.9%; p = 0.0006) when compared with cells cultured alone or with control human IgG. The suppressive effect of CD4+CD25+ T cells presented as a decrease of TNF-α production by stimulated CD4+CD25+ (effector T cells) was further increased by adding IVIg to cell culture. We hereby demonstrate an additional mechanism by which IVIg could maintain self-tolerance and decrease immune-mediated inflammation. The Journal of Immunology, 2007, 179: 5571–5575.

The usage of i.v. Ig (IVIg) has been proven to be beneficial in various autoimmune and immune-mediated inflammatory conditions such as idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, and dermatomyositis (1, 2). In addition, IVIg is widely used (empirically) in other autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, and various vasculitides (3–5). The long list of reported mechanisms by which IVIg induces its immunomodulatory effects, points to the many pathways that are targeted by this unique therapy.

The presence of a wide range of anti-idiotypic Abs in IVIg was reported to be one of the main mechanisms for the beneficial effect of this therapy (6, 7). These Abs bind pathogenic autoantibodies and prevent them from targeting autoantigens and the formation of immune complexes. IVIg was shown to induce a reversible blockade of the Fc receptors on phagocytic cells by saturating or down-regulating the affinity of Fc receptors, disabling by that sensitized phagocytic cells to function in ITP (8). In addition IVIg is protective against complement-mediated tissue damage, when it inhibits the binding of C3; C4 to target structures, such as in dermatomyositis (9). The ability of IVIg to neutralize proinflammatory cytokines such as TNF-α, was also proven in some patients to be one of the important mechanisms by which IVIg is beneficial in rheumatoid arthritis (RA) or Kawasaki disease (10).

Considering the effect of serum factors as IFN-α (IFN-α), on the activity of dendritic cells (DCs), the effects of IVIg on the differentiation of DCs mediated by serum from SLE patients was assessed (11). IVIg was found to abrogate DC differentiation induced by IFN-α present in serum from SLE patients by 36%. These findings indicate that IVIg down-regulate DCs by inhibiting the ingestion of nucleosomes by immature DCs. Inhibition of expression of HLA and CD80/CD86 on DCs offers a plausible explanation for the efficacy of IVIg in SLE and other immune-mediated inflammatory conditions.

Recently, IVIg was reported to induce apoptosis in human lymphocytes and monocytes via Fas-mediated pathway (12). It has also been shown to inhibit endothelial cell proliferation and mRNA expression of cytokines, adhesion molecules and chemokines in endothelial cells (13). In a most recent study, B cell-activating factor was reported to be a new target for IVIg treatment in autoimmune diseases (14).

Naturally occurring CD4+CD25+ regulatory T cells (Tregs), are engaged in dominant control of self-reactive T cells, contributing to the maintenance of immunologic self-tolerance. Their repertoire of Ag specificities is as broad as that of naïve T cells, and they are capable of recognizing both self and nonself Ags, thus enabling them to control various immune responses. In addition to Ag recognition, signals through various accessory molecules (TLRs) and via the up-regulation of FoxP3 (a specific T regulatory transcription factor) and or inhibitory cytokines such as IL-10 and TGF-β, control their activation, expansion, and tune their suppressive activity (15). Treg cells are characterized by their ability to suppress effector T cells of either TH1 or TH2 phenotype involved in mediating inflammation in a cell contact and Ag-specific manner. Many studies have already shown that the lower number of Treg cells as well as alterations in their suppressive function may lead to the development of autoimmune disease in otherwise normal animal and human models (16–18).
In previous studies we demonstrated the increase of Treg numbers as well as the restoration of their sensitivity to undergo spontaneous apoptosis following anti-TNF therapy in patients with active rheumatoid arthritis. This suggested that Treg cells are a potential target for the treatment of patients with autoimmune diseases.

The possible increase of Treg suppressive activity by IVIg therapy has yet to be investigated, and therefore we asked to analyze whether in vitro IVIg could possibly increase the expression of intracellular IL-10, TGF-β and the transcription factor FoxP3 in Treg cells. We also show that IVIg increase the suppressive abilities of Treg cells in decreasing the secretion of TNF-α by effector CD4+ T cells.

Materials and Methods

Study material

PBMCs, isolated CD4+ T cells, and purified CD4+CD25+ Treg cells were obtained from 12 healthy individuals aged 24–36 years. Informed consent was obtained, and the study was approved by the local Helsinki committee at Bnai-Zion Medical Center (Haifa, Israel).

The source of IVIg was Omrigam (Omrix Pharmaceuticals). C-IgG from one healthy individual (as a control for IVIg) was loaded on anti-human IgG Sepharose column (Sigma-Aldrich). The bound IgG was eluted by using 5M MgCl2 and dialyzed against PBS (pH 7.4). Both affinities purified individual IgG and IVIg were dialyzed overnight against enriched RPMI 1640 at 4°C and adjusted to be used in cell culture at final concentration of 6 mg/ml.

Purification of T cell subsets

PBMCs were isolated on Lymphoprep. CD4+ T cells were isolated by negative selection using the CD4 isolation kit for magnetic separation (MAC system; Miltenyi Biotec) according to the manufacturer’s instructions, achieving $>95\%$ purity. For CD4+CD25+ lymphocyte isolation, CD4+ T cells were incubated with mouse anti-human CD25 MicroBeads (20 μl/10^7 cells) and separated into CD4+CD25+ and CD4+CD25− T cells on a positive selection column. A representative isolation of 92.8% Treg cells is shown by FACS analysis.

Flow cytometric analysis

To analyze the expression of intracellular IL-10, TGF-β and the transcription factor FoxP3, purified CD4+ T lymphocytes were cultured in RPMI 1640 supplemented with 10% FCS, 2 mm l-glutamine, 100 U/ml penicillin, 5 U/ml streptomycin, and recombinant human IL-2 at a concentration of 5 U/ml. "Cells were cultured in 24-well plates (Cellstar, Greiner bio-one) at a final concentration of 1 x 10^6 cells/well in triplicates alone or supplemented with IVIg (6 mg/ml) or with human C-IgG (6 mg/ml) during 12 h. After washing the cells, staining with CD4-FITC and CD25-PC5 (IoTest; Beckman Coulter) for surface expression was performed. Subsequently, cells were washed, fixed, permeabilized (cell permeabilization kit; Caltag Laboratories) and stained for the detection of intracellular cytokines using PE-conjugated anti-IL-10 (R&D Systems) or anti-TGFβ (IQ Products). Additionally, cells were washed, fixed, permeabilized, and stained with mouse anti-human CD25 MicroBeads (20.8% vs 33.7% p = 0.008), whereas IgG did not change significantly the extent of expression. A significant increase in the expression of TGF-β following the addition of IVIg (17.7% vs 29.8% p = 0.02), contrary to IgG which did not affect this expression. C. Here also, the addition of IVIg increased FoxP3 expression (20.8 ± 5.2% vs 33.7 ± 5.9% p = 0.0006) but IgG did not. Data are expressed as mean values ± SD.

Summary of intracellular cytokine expression in T reg cells (CD4+CD25(high)), cultured during 12 h alone (baseline) or following the addition of IVIg (6 mg/ml) or human C-IgG (6 mg/ml). A. The expression of baseline IL-10 was significantly increased following the addition of IVIg to culture (20.7 ± 4.7% vs 34.2 ± 5.2%; p = 0.008), whereas IgG did not change significantly the extent of expression. B. A significant increase in the expression of TGF-β following the addition of IVIg (17.7 ± 8.5% vs 29.8 ± 13%; p = 0.02), contrary to IgG which did not affect this expression. C. Here also, the addition of IVIg increased FoxP3 expression (20.8 ± 5.2% vs 33.7 ± 5.9%; p = 0.0006) but IgG did not. Data are expressed as mean values ± SD.
FIGURE 4. A representative figure of IL-10, TGF-β, and FoxP3 expressions at baseline and following IVIg and IgG additions. CD4⁺ T cells were cultured in 24-well plates at a final concentration of 1 × 10⁶ cells/well in triplicates alone or supplemented with IVIg (6 mg/ml) or with human C-IgG (6 mg/ml) during 12 h. Cells were analyzed by flow cytometry. Gates were set so that the CD4⁺CD25⁺ population was based on the isotype control whereas the CD25⁺ population was determined relative to the low intensity of CD25 staining found on non-CD4 T cells. Baseline IL-10, TGF-β, and FoxP3 expressions were increased following the addition of IVIg. However, the addition of C-IgG did not change baseline expression.

Cytokine detection
CD4⁺CD25⁺ T cells were cultured either alone or mixed at 1:4 ratio (10⁶ cells/well) with CD4⁺CD25⁺ and stimulated with 10 μg/ml plate bound anti-CD3 and 1 μg/ml soluble anti-CD28 Abs (Bioscience). Cultures were set in triplicates in 96-well plates (Nunc) alone or supplemented with IVIg (6 mg/ml) or with C-IgG (6 mg/ml) and maintained for 16, 24, and 36 h. Supernatants were collected and analyzed for the presence of TNF-α.

 Determination of TNF-α levels in culture supernatants
A sandwich ELISA (DuoSet; R&D Systems) was used to measure TNF-α levels in the culture supernatants. 96-well plates (Costar 3590) were utilized to coat the capture Ab. The substrate solution was tetramethylbenzidine (DakoCytomation). TNF-α levels were expressed as picograms of TNF-α per milligram of cell protein. Treg cells protein level was determined by the Lowry method (19). To normalize the results between different individuals, the pg/mg cell protein levels of TNF-α, measured in the supernatants of cultured cells, was considered as 100%. The change in TNF-α secretion by CD4⁺ T effector cells in various conditions was expressed as percentage of change from baseline.

Statistical analyses
Comparison of intracellular cytokine expression as well as of TNF secretion between each of the two conditions was performed using the paired Student t test or the paired Wilcoxon test as needed. Two-tailed t values of 0.05 or less were considered to be statistically significant. Data are expressed as mean values ± SD.

Results
Based on their CD25 expression, human CD4⁺ T cells can be divided into three populations: CD25high, CD25low, and CD25cells. The gate for CD4⁺CD25high was drawn based on the top of CD4⁺ T cells expressing high levels of CD25 in the peripheral blood of each patient (Fig. 2).

 Intracellular cytokine expression
Baseline expression of intracellular IL-10, TGF-β, and the transcription factor FoxP3 in CD4⁺CD25high Treg cells (before the incubation with IVIg, or C-IgG) was as follows: IL-10 (mean 20.7 ± 4.7%, n = 12), TGF-β (mean 17.7 ± 8.5%, n = 12), and FoxP3 (mean 20.8 ± 5.2%, n = 12). The addition of IVIg to CD4⁺ T cells induced a significant elevation in the expression of intracellular cytokines in CD4⁺CD25high Treg cells: IL-10 (20.7 ± 4.7% vs 34.2 ± 5.2%; p = 0.008), TGF-β (17.7 ± 8% vs 29.8 ± 13%; p = 0.02) and FoxP3 (20.8 ± 5.2% vs 33.7 ± 5.9%; p = 0.0006). In contrast to IVIg the addition of C-IgG into cultured CD4⁺ T cells, did not statistically modify the level of intracellular cytokines compared with that of the baseline. See a summary of 12 experiments (Fig. 3) and also a representative experiment (Fig. 4).

Discussion
Among the several mechanisms that play role in maintaining peripheral self-tolerance is the existence of a unique CD4⁺CD25⁺ population of naturally occurring regulatory T cells that actively prevent both the activation and the effector function of autoreactive T cells that have escaped different mechanisms of tolerance (20–22).
Many studies have established the occurrence of numeric decrease as well as the defective regulatory function of CD4+CD25+ Treg cells in patients with active SLE. These alterations were mostly associated with a marked decrease in FoxP3 mRNA and protein expression in Treg cells from patients with active but not inactive SLE (23).

In a recent study, in vitro activation of CD4+CD25high Treg cells from patients with active SLE, increased the expression of FoxP3 and restored their suppressive function, suggesting that strategies to enhance the function of these cells might benefit patients with autoimmune diseases (24). The idea of using various therapeutic regimens to restore the function of Treg cells mainly converting transient Treg activity into a stable phenotype was also reported in previous studies.

In agreement with these findings, the interaction of CD4+CD25+ Treg cells with activated monocytes in the joint of RA patients might lead to diminished suppressive activity of Treg cells in vivo, thus contributing to the chronic inflammation in RA (25). With these results in mind, and the fact that the blockade of TNF-α by therapy with anti-TNF has proven to be beneficial by inhibiting inflammation and preventing joint damage in RA patients, one may assume that this clinical effect might be mediated in part by a restoration of the defective function of CD4+CD25+ Treg cells in patients with active RA. In a previous study CD4+CD25+ Treg cells were shown to display increased proclivity to undergo spontaneous apoptosis in active RA. Alterations in CD4+CD25+ cell apoptosis and cell count were found to correlate with RA disease activity. Reversal of these deviations from normal was documented in association with the beneficial outcome of infliximab therapy (26).

In this regard, glucocorticoids were reported to affect the activity of Treg cells on the basis of FoxP3 and cytokine expression (27). FoxP3 mRNA expression was significantly increased in asthmatic patients receiving inhaled glucocorticoid treatment, systemic glucocorticoid treatment, or both. The frequency of CD25+ T cells significantly increased after systemic glucocorticoid treatment. In addition, glucocorticoids induced IL-10 and FoxP3 expression in short-term and long-term cultures in vitro. This study showed that treatment with glucocorticoids may promote or initiate differentiation toward Treg cells by FoxP3-dependent mechanism. Thus, targeting these cells that aim to increase the expression of these molecules and their suppressive activity could become one of the tools by which self-tolerance is restored.

Here, and in agreement with all the above, we show for the first time that IVIg was proven by a unique mechanism to enhance the suppressive activity of CD4+CD25+ Treg cells. In this study we demonstrate that the addition of IVIg to CD4+ cells increased intracellular expression of IL-10, TGF-β and FoxP3 when we gazed on CD4+CD25high T cells, suggesting that IVIg have the properties of directly affecting Treg cells. We then established that the addition of IVIg to the culture of cells increased the suppressive function of Treg cells by further attenuating TNF secretion by CD4+ effector cells when IVIg was added to CD25+ cells.

The mechanisms by which IVIg could possibly affect the function of Treg cells is still not clear enough. Increased expression of intracellular IL-10 in Treg cells could inhibit the production of proinflammatory cytokines by Th1 such as TNF-α. In this regard, IVIg treatment resulted in the down-regulation of the Th1-type cytokine TNF-α, and the up-regulation of the Th2-type cytokine IL-10 (28). As supported by several experimental studies, IVIg regulate crucial steps of T cell-mediated immune responses. These effects involve the modulation of activation, proliferation, differentiation, apoptosis, and effector mechanisms of T cells. The pattern of IVIg-T cell interactions is complex, as IVIg may directly
bind to regulatory structures on T cells, or modulate T cell functions indirectly via soluble or cellular components of the immune system (29).

It is well established that autoantibodies directed against "public" idiotypes present in the first CDR (CDR1) and the third framework (FR3) of the Vβ gene. Products are generated in response to the over-production of autodestructive T cells bearing particular Vβ gene products and function to down-regulate the expression of these T cells. Specificity characterizations of polyclonal and monoclonal IgM and IgG autoantibodies from SLE patients were reported (30). Because Abs of these specificities are present in IVIg preparations, the immunomodulatory effects of Abs directed against TCR variable domains may account, at least in part, for the efficacy of IVIG in the therapy of autoimmune diseases. One may speculate that IVIG contains a wide range of natural autoantibodies that are directed against TCR variable domains on Treg cells, and that in contrast to effector CD4+ T cells, they increase their activity by enhancing the FoxP3 expression or by increasing the activity of CTLA-4 on these cells. The fact that Ig influences the composition of T the cell repertoire by increasing its diversity allows for a much wider application of this molecule in the clinical practice, aiming to improve the diversity of the reconstituted immune repertoires (31).

Our present study reports on a unique effect of IVIG by which it restores the suppressive function of Treg cells which may add to its beneficial properties in the treatment of autoimmune diseases. The new role of the Ig molecule may help to explain several effects that IVIG has in the T cell compartment, such as modulation of the activation and function of Treg cells. Further studies are planned to better understand the precise mechanisms by which IVIG immunomodulate this unique and important subset of T cells.

Disclosures

The authors have no financial conflict of interest.

References